MV4–11 cells are relatively resistant to ara-C in vitro (2 μM treatment for 24 h only results in 20% Annexin V-positive cells).17 When treated on a daily schedule, venetoclax, voruciclib, and the combination resulted in ILS of 12%, 6.7%, and 14.7%, respectively (Fig. S2b), supporting the use of an intermittent schedule, although further investigation in other AML xenograft mouse models is warranted. This evidence concerns the gene ANXA5 and acute myeloid leukemia.